(TLRY) Tilray - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 766m USD | Total Return: 38% in 12m

Cannabis Products, Beverages, Wellness, Distribution
Total Rating 18
Safety 41
Buy Signal -0.48
Drug Manufacturers - Specialty & Generic
Industry Rotation: -1.6
Market Cap: 766M
Avg Turnover: 16.3M USD
ATR: 6.51%
Peers RS (IBD): 12.7
Risk 5d forecast
Volatility88.6%
Rel. Tail Risk-27.2%
Reward TTM
Sharpe Ratio0.76
Alpha-26.46
Character TTM
Beta2.202
Beta Downside1.375
Drawdowns 3y
Max DD89.12%
CAGR/Max DD-0.40
EPS (Earnings per Share) EPS (Earnings per Share) of TLRY over the last years for every Quarter: "2021-02": -0.06, "2021-05": 0.27, "2021-08": -0.08, "2021-11": 0.03, "2022-02": 0.09, "2022-05": -0.9, "2022-08": -0.13, "2022-11": -0.11, "2023-02": -1.9, "2023-05": -0.15, "2023-08": -0.1, "2023-11": -0.07, "2024-02": -0.12, "2024-05": -0.04, "2024-08": -0.04, "2024-11": -0.0026, "2025-02": -0.8691, "2025-05": 0.02, "2025-08": -0.0003, "2025-11": -0.02, "2026-02": 0.02,
EPS CAGR: 18.87%
EPS Trend: 41.7%
Last SUE: -0.17
Qual. Beats: 0
Revenue Revenue of TLRY over the last years for every Quarter: 2021-02: 188.91311, 2021-05: 183.809457, 2021-08: 211.108577, 2021-11: 198.551879, 2022-02: 193.079243, 2022-05: 193.278939, 2022-08: 201.169982, 2022-11: 194.476939, 2023-02: 198.077716, 2023-05: 248.096324, 2023-08: 239.673291, 2023-11: 262.375622, 2024-02: 255.645182, 2024-05: 313.230316, 2024-08: 269.839351, 2024-11: 295.055765, 2025-02: 268.340631, 2025-05: 308.104681, 2025-08: 287.778953, 2025-11: 303.852928, 2026-02: 282.201583,
Rev. CAGR: 10.62%
Rev. Trend: 87.0%
Last SUE: 0.71
Qual. Beats: 0

Warnings

Share dilution 24.2% YoY - potential capital distress

Interest Coverage Ratio -67.6 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: TLRY Tilray

Tilray Brands, Inc. (TLRY) is a Canadian company operating in the cannabis and consumer products sectors. The company is involved in the research, cultivation, processing, and distribution of medical cannabis globally. This business model is common among Canadian licensed producers.

TLRYs operations are divided into four segments: Beverage, Cannabis, Distribution, and Wellness. Beyond cannabis, the company produces and sells alcoholic beverages, hemp-based foods, and resells pharmaceutical and wellness products. This diversification strategy is prevalent among cannabis companies seeking to expand revenue streams beyond regulated cannabis markets.

The company markets its products under numerous brands, including Tilray, Aphria, SweetWater Brewing, and Manitoba Harvest. It distributes products to a wide range of customers, including retailers, wholesalers, patients, and governments. For a deeper dive into Tilrays brand portfolio and market performance, consider exploring ValueRays detailed reports.

Headlines to Watch Out For
  • Cannabis legalization progress impacts revenue growth
  • Beverage alcohol sales drive segment performance
  • Regulatory hurdles affect international expansion
  • Competition intensifies in global cannabis markets
  • Input costs and supply chain disruptions pressure margins
Piotroski VR‑10 (Strict) 2.0
Net Income: -1.85b TTM > 0 and > 6% of Revenue
FCF/TA: -0.05 > 0.02 and ΔFCF/TA -2.25 > 1.0
NWC/Revenue: 39.02% < 20% (prev 53.43%; Δ -14.41% < -1%)
CFO/TA -0.03 > 3% & CFO -55.8m > Net Income -1.85b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.79 > 1.5 & < 3
Outstanding Shares: last quarter (112.7m) vs 12m ago 24.05% < -2%
Gross Margin: 27.67% > 18% (prev 0.31%; Δ 2.74k% > 0.5%)
Asset Turnover: 33.82% > 50% (prev 23.32%; Δ 10.49% > 0%)
Interest Coverage Ratio: -67.61 > 6 (EBITDA TTM -1.84b / Interest Expense TTM 28.9m)
Altman Z'' -15.00
A: 0.22 (Total Current Assets 718.8m - Total Current Liabilities 257.5m) / Total Assets 2.07b
B: -2.37 (Retained Earnings -4.92b / Total Assets 2.07b)
C: -0.56 (EBIT TTM -1.96b / Avg Total Assets 3.50b)
D: -9.04 (Book Value of Equity -4.96b / Total Liabilities 549.1m)
Altman-Z'' Score: -19.52 = D
Beneish M -3.97
DSRI: 0.77 (Receivables 118.4m/149.3m, Revenue 1.18b/1.15b)
GMI: 1.11 (GM 27.67% / 30.83%)
AQI: 1.02 (AQ_t 0.64 / AQ_t-1 0.64)
SGI: 1.03 (Revenue 1.18b / 1.15b)
TATA: -0.86 (NI -1.85b - CFO -55.8m) / TA 2.07b)
Beneish M-Score: -3.97 (Cap -4..+1) = AAA
What is the price of TLRY shares? As of April 14, 2026, the stock is trading at USD 6.72 with a total of 2,839,367 shares traded.
Over the past week, the price has changed by +0.90%, over one month by -2.47%, over three months by -28.43% and over the past year by +38.04%.
Is TLRY a buy, sell or hold? Tilray has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold TLRY.
  • StrongBuy: 4
  • Buy: 0
  • Hold: 8
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TLRY price?
Analysts Target Price 10 49.4%
Tilray (TLRY) - Fundamental Data Overview as of 12 April 2026
P/E Forward = 1000.0
P/S = 0.8922
P/B = 1.1818
Revenue TTM = 1.18b USD
EBIT TTM = -1.96b USD
EBITDA TTM = -1.84b USD
Long Term Debt = 223.2m USD (from longTermDebt, last quarter)
Short Term Debt = 33.5m USD (from shortTermDebt, last quarter)
Debt = 317.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 112.5m USD (from netDebt column, last quarter)
Enterprise Value = 862.9m USD (765.7m + Debt 317.1m - CCE 219.9m)
Interest Coverage Ratio = -67.61 (Ebit TTM -1.96b / Interest Expense TTM 28.9m)
EV/FCF = -9.02x (Enterprise Value 862.9m / FCF TTM -95.7m)
FCF Yield = -11.09% (FCF TTM -95.7m / Enterprise Value 862.9m)
FCF Margin = -8.10% (FCF TTM -95.7m / Revenue TTM 1.18b)
Net Margin = -156.2% (Net Income TTM -1.85b / Revenue TTM 1.18b)
Gross Margin = 27.67% ((Revenue TTM 1.18b - Cost of Revenue TTM 854.9m) / Revenue TTM)
Gross Margin QoQ = 26.58% (prev 26.43%)
Tobins Q-Ratio = 0.42 (Enterprise Value 862.9m / Total Assets 2.07b)
Interest Expense / Debt = 2.14% (Interest Expense 6.78m / Debt 317.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.54b (EBIT -1.96b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.79 (Total Current Assets 718.8m / Total Current Liabilities 257.5m)
Debt / Equity = 0.20 (Debt 317.1m / totalStockholderEquity, last quarter 1.56b)
 Debt / EBITDA = -0.06 (negative EBITDA) (Net Debt 112.5m / EBITDA -1.84b)
 Debt / FCF = -1.18 (negative FCF - burning cash) (Net Debt 112.5m / FCF TTM -95.7m)
 Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = -52.82% (Net Income -1.85b / Total Assets 2.07b)
RoE = -92.82% (Net Income TTM -1.85b / Total Stockholder Equity 1.99b)
RoCE = -88.41% (EBIT -1.96b / Capital Employed (Equity 1.99b + L.T.Debt 223.2m))
 RoIC = -85.84% (negative operating profit) (NOPAT -1.54b / Invested Capital 1.80b)
 WACC = 10.20% (E(765.7m)/V(1.08b) * Re(13.73%) + D(317.1m)/V(1.08b) * Rd(2.14%) * (1-Tc(0.21)))
Discount Rate = 13.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.81%
 [DCF] Fair Price = unknown (Cash Flow -95.7m)
 EPS Correlation: 41.71 | EPS CAGR: 18.87% | SUE: -0.17 | # QB: 0
Revenue Correlation: 87.03 | Revenue CAGR: 10.62% | SUE: 0.71 | # QB: 0
EPS next Quarter (2026-08-31): EPS=-0.14 | Chg7d=-0.140 | Chg30d=-0.140 | Revisions Net=-1 | Analysts=3
EPS next Year (2027-05-31): EPS=-0.34 | Chg7d=-0.273 | Chg30d=-0.273 | Revisions Net=-3 | Growth EPS=+39.5% | Growth Revenue=+24.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle